Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 457-466

  El Jurdi, Najla ^a   Reljic, Tea ^b   Kumar, Ambuj ^b,c   Pidala, Joseph ^c   Bazarbachi, Ali ^a   Djulbegovic, Benjamin ^b,c   Kharfan Dabaja, Mohamed A ^a,c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

DLI; donor lymphocyte infusion; lymphoid malignancies; systematic review

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LYMPHOCYTE TRANSFUSION; LYMPHOMA; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84877282791     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.31     Document Type: Article

References (45)

1. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
2. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5), 2041-2050 (1995).
3. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15(2), 433-444 (1997).
4. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 41(5), 483-493 (2008).
5. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177-188 (1986).
6. Stuart A, Ord K. Kendall's Advanced Theory of Statistics. Wiley, NJ, USA (1994).
7. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S (Eds). Wiley, NJ, USA (2011).
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses the PRISMA statement. BMJ 339, b2535 (2009).
9. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87(6), 2195-2204 (1996).
10. Atra A, Millar B, Shepherd V et al. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. Br. J. Haematol. 97(1), 165-168 (1997).
11. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk. Lymphoma 32(3-4), 317-325 (1999).
12. Collins RH Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26(5), 511-516 (2000).
13. Porter DL, Collins RH Jr, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95(4), 1214-1221 (2000).
14. Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant. 26(7), 769-774 (2000).
15. Choi SJ, Lee JH, Kim S et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion a prospective study. Bone Marrow Transplant. 36(2), 163-169 (2005).
16. Michallet AS, Nicolini F, Furst S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 35(6), 601-608 (2005).
17. Levine JE, Barrett AJ, Zhang MJ et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 42(3), 201-205 (2008).
18. Yegin ZA, Ozkurt ZN, Aki SZ, Sucak GT. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transfus. Apher. Sci. 42(3), 239-245 (2010).
19. Ritgen M, Stilgenbauer S, von Neuhoff N et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status implications of minimal residual disease measurement with quantitative PCR. Blood 104(8), 2600-2602 (2004).
20. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90(10), 4206-4211 (1997).
21. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91(10), 3671-3680 (1998).
22. Verdonck LF, Petersen EJ, Lokhorst HM et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation impact of infused and residual donor T cells. Bone Marrow Transplant. 22(11), 1057-1063 (1998).
23. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation predictive factors for response and long-term outcome. J. Clin. Oncol. 18(16), 3031-3037 (2000).
24. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 26(11), 1179-1184 (2000).
25. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97(9), 2574-2579 (2001).
26. Huff CA, Fuchs EJ, Noga SJ et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma importance of allogeneic T cells. Biol. Blood Marrow Transplant. 9(5), 312-319 (2003).
27. Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma limited efficacy of graft-versus-tumor activity. Biol. Blood Marrow Transplant. 9(4), 257-265 (2003).
28. Lokhorst HM, Wu K, Verdonck LF et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103(11), 4362-4364 (2004).
29. van de Donk NW, Kroger N, Hegenbart U et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 37(12), 1135-1141 (2006).
30. Porter DL, Luger SM, Duffy KM et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol. Blood Marrow Transplant. 7(4), 230-238 (2001).
31. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100(13), 4310-4316 (2002).
32. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 32(12), 1159-1163 (2003).
33. Anderlini P, Acholonu SA, Okoroji GJ et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 34(6), 511-514 (2004).
34. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non- Hodgkin lymphoma. Blood 104(13), 3865-3871 (2004).
35. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365(9475), 1934-1941 (2005).
36. Peggs KS, Sureda A, Qian W et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br. J. Haematol. 139(1), 70-80 (2007).
37. Bishop MR, Dean RM, Steinberg SM et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann. Oncol. 19(11), 1935-1940 (2008).
38. Bloor AJ, Thomson K, Chowdhry N et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 14(1), 50-58 (2008).
39. Thomson KJ, Morris EC, Milligan D et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J. Clin. Oncol. 28(23), 3695-3700 (2010).
40. Peggs KS, Kayani I, Edwards N et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J. Clin. Oncol. 29(8), 971-978 (2011).
41. Gribben JG, Zahrieh D, Stephans K et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106(13), 4389-4396 (2005).
42. Marks DI, Lush R, Cavenagh J et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9), 3108-3114 (2002).
43. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 36(5), 437-441 (2005).
44. Peggs KS, Thomson K, Hart DP et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation toxicity, chimerism, and disease responses. Blood 103(4), 1548-1556 (2004).
45. Huff CA, Fuchs EJ, Smith BD et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol. Blood Marrow Transplant. 12(4), 414-421 (2006).